Journal ArticleMol Genet Metab · February 2024
INTRODUCTION: The standard of care for patients with infantile-onset Pompe disease (IOPD) is enzyme replacement therapy (ERT), which does not cross the blood brain barrier. While neuromuscular manifestations of IOPD are well-described, central nervous syst ...
Full textLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · December 2023
Individuals with Down syndrome (DS) have been particularly impacted by respiratory conditions, such as pneumonia. However, the description of co-occurring recurrent infections, the response to pneumococcal immunization, and the association of these was pre ...
Full textLink to itemCite
Chapter · February 19, 2021
Down syndrome is the most common identifiable genetic cause of intellectual disability. The facial appearance of individuals with Down syndrome is highly characteristic and is frequently associated with other minor anomalies and malformations of other body ...
Full textOpen AccessLink to itemCite
Journal ArticleMol Genet Metab Rep · December 2020
PURPOSE: To improve our understanding of the behavioral, social, and emotional functioning of children and adolescents with Pompe disease. METHOD: Parents/guardians of 21 children (age 5-18y) with infantile (IPD) or late-onset (LOPD) Pompe disease on long- ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Intellect Dev Disabil · November 1, 2020
Although norm-referenced scores are essential to the identification of disability, they possess several features which affect their sensitivity to change. Norm-referenced scores often decrease over time among people with neurodevelopmental disorders who ex ...
Full textLink to itemCite
Journal ArticleNeurology · August 2020
ObjectiveTo characterize the extent of CNS involvement in children with Pompe disease using brain MRI and developmental assessments.MethodsThe study included 14 children (ages 6-18 years) with infantile Pompe disease (IPD) (n = 12) or lat ...
Full textOpen AccessCite
Journal ArticleAm J Med Genet A · January 2019
Measures of adaptive behavior are important in the assessment and treatment of individuals with intellectual disabilities (ID). The purpose of the current study was to evaluate the stability of an established and a novel measure of adaptive behavior over t ...
Full textLink to itemCite
Journal ArticleAm J Hum Genet · August 2, 2018
Interferon regulatory factor 2 binding protein-like (IRF2BPL) encodes a member of the IRF2BP family of transcriptional regulators. Currently the biological function of this gene is obscure, and the gene has not been associated with a Mendelian disease. Her ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · November 2017
We systematically reviewed the measures used in pharmaceutical trials in children/adults with Down syndrome without dementia. Our purpose was to identify developmentally appropriate outcome measures capable of detecting changes in cognitive and adaptive fu ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Med Genet A · November 2017
Although an increasing number of clinical trials have been developed for cognition in Down syndrome, there has been limited success to date in identifying effective interventions. This review describes the progression from pre-clinical studies with mouse m ...
Full textLink to itemCite
Journal ArticleMol Genet Metab · June 2017
This study examines the long-term cognitive and academic outcomes of 11 individuals with infantile onset Pompe disease (IOPD) (median age=11years, 1month, range=5years, 6months through 17years of age) treated with enzyme replacement therapy from an early a ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · June 2016
Individuals with Down syndrome (DS) have decreased cholinergic function and an uneven profile of cognitive abilities, with more pronounced deficits in learning, memory, and expressive language. Cholinesterase inhibitors may improve cognitive function in ad ...
Full textLink to itemCite
Journal ArticleFront Behav Neurosci · 2015
Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development ...
Full textLink to itemCite
Journal ArticleMol Genet Metab · March 2012
This report describes the cognitive development of 17 children with infantile Pompe disease who participated in a 52-week clinical trial of enzyme replacement therapy (ERT) via biweekly infusion of Myozyme® (alglucosidase alfa). Subjects were six months of ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · February 15, 2012
This report documents the long-term cognitive and adaptive outcome of children with infantile Pompe disease. Specifically, we describe the cognitive and adaptive functioning of seven children with classic infantile Pompe disease and two children with atypi ...
Full textLink to itemCite
Journal ArticleMol Genet Metab · February 2024
INTRODUCTION: The standard of care for patients with infantile-onset Pompe disease (IOPD) is enzyme replacement therapy (ERT), which does not cross the blood brain barrier. While neuromuscular manifestations of IOPD are well-described, central nervous syst ...
Full textLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · December 2023
Individuals with Down syndrome (DS) have been particularly impacted by respiratory conditions, such as pneumonia. However, the description of co-occurring recurrent infections, the response to pneumococcal immunization, and the association of these was pre ...
Full textLink to itemCite
Chapter · February 19, 2021
Down syndrome is the most common identifiable genetic cause of intellectual disability. The facial appearance of individuals with Down syndrome is highly characteristic and is frequently associated with other minor anomalies and malformations of other body ...
Full textOpen AccessLink to itemCite
Journal ArticleMol Genet Metab Rep · December 2020
PURPOSE: To improve our understanding of the behavioral, social, and emotional functioning of children and adolescents with Pompe disease. METHOD: Parents/guardians of 21 children (age 5-18y) with infantile (IPD) or late-onset (LOPD) Pompe disease on long- ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Intellect Dev Disabil · November 1, 2020
Although norm-referenced scores are essential to the identification of disability, they possess several features which affect their sensitivity to change. Norm-referenced scores often decrease over time among people with neurodevelopmental disorders who ex ...
Full textLink to itemCite
Journal ArticleNeurology · August 2020
ObjectiveTo characterize the extent of CNS involvement in children with Pompe disease using brain MRI and developmental assessments.MethodsThe study included 14 children (ages 6-18 years) with infantile Pompe disease (IPD) (n = 12) or lat ...
Full textOpen AccessCite
Journal ArticleAm J Med Genet A · January 2019
Measures of adaptive behavior are important in the assessment and treatment of individuals with intellectual disabilities (ID). The purpose of the current study was to evaluate the stability of an established and a novel measure of adaptive behavior over t ...
Full textLink to itemCite
Journal ArticleAm J Hum Genet · August 2, 2018
Interferon regulatory factor 2 binding protein-like (IRF2BPL) encodes a member of the IRF2BP family of transcriptional regulators. Currently the biological function of this gene is obscure, and the gene has not been associated with a Mendelian disease. Her ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · November 2017
We systematically reviewed the measures used in pharmaceutical trials in children/adults with Down syndrome without dementia. Our purpose was to identify developmentally appropriate outcome measures capable of detecting changes in cognitive and adaptive fu ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Med Genet A · November 2017
Although an increasing number of clinical trials have been developed for cognition in Down syndrome, there has been limited success to date in identifying effective interventions. This review describes the progression from pre-clinical studies with mouse m ...
Full textLink to itemCite
Journal ArticleMol Genet Metab · June 2017
This study examines the long-term cognitive and academic outcomes of 11 individuals with infantile onset Pompe disease (IOPD) (median age=11years, 1month, range=5years, 6months through 17years of age) treated with enzyme replacement therapy from an early a ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · June 2016
Individuals with Down syndrome (DS) have decreased cholinergic function and an uneven profile of cognitive abilities, with more pronounced deficits in learning, memory, and expressive language. Cholinesterase inhibitors may improve cognitive function in ad ...
Full textLink to itemCite
Journal ArticleFront Behav Neurosci · 2015
Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development ...
Full textLink to itemCite
Journal ArticleMol Genet Metab · March 2012
This report describes the cognitive development of 17 children with infantile Pompe disease who participated in a 52-week clinical trial of enzyme replacement therapy (ERT) via biweekly infusion of Myozyme® (alglucosidase alfa). Subjects were six months of ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · February 15, 2012
This report documents the long-term cognitive and adaptive outcome of children with infantile Pompe disease. Specifically, we describe the cognitive and adaptive functioning of seven children with classic infantile Pompe disease and two children with atypi ...
Full textLink to itemCite
Journal ArticleJ Genet Couns · February 2012
Using a multi-group cross-sectional design, we explored self-concept related to parental role salience and enactment in 53 young women (14 to 24 years) with knowledge they were either carriers, non-carriers, or could be a carrier of fragile X syndrome (FXS ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · December 2010
The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS). Intervention comprise ...
Full textLink to itemCite
Journal ArticleJ Child Adolesc Psychopharmacol · December 2010
Following the completion of a 20-week, open-label study of the safety and efficacy of liquid rivastigmine for adolescents with Down syndrome, 5 of the 10 adolescents in the clinical trial continued long-term rivastigmine therapy and 5 did not. After an ave ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Intellect Disabil Res · July 2010
BACKGROUND: Current research suggests that depression and anxiety may be common problems in women with the fragile X (FMR1) premutation. METHODS: To learn more about this in a clinical setting, we asked 33 women with the FMR1 premutation and 20 women witho ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · August 2009
Featured Publication
The objective of our study was to assess the efficacy and safety of donepezil in young adults with Down syndrome (DS) but no evidence of Alzheimer disease (AD). A 12-week, randomized, double-blind, placebo-controlled study with a 12-week, open-label extens ...
Full textLink to itemCite
Journal ArticleJ Genet Couns · August 2009
Featured Publication
Little is known about how and what genetic risk information parents communicate to their children and even less is known about what children hear and remember. To address this void, we explored how genetic risk information was learned, what information was ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · June 2009
Featured Publication
We report here on our findings from adolescent and young adult females (ages 14-25) with a family history of fragile X syndrome regarding their perceptions of the optimal ages for (1) learning fragile X is inherited, (2) learning one could be a carrier for ...
Full textLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · February 15, 2008
Featured Publication
The purpose of this study is to describe the interplay of adolescent girls' and young womens' self-concept, coping behaviors, and adjustment associated with knowledge of genetic risk for fragile X syndrome. We will report here findings on self-concept. Usi ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · July 1, 2007
Featured Publication
There is growing evidence to support the use of early central cholinergic enhancement to improve cognitive functioning in individuals with Down syndrome (DS). This report summarizes preliminary safety and cognitive efficacy data for seven children (8-13 ye ...
Full textLink to itemCite
Journal ArticleJ Child Adolesc Psychopharmacol · December 2006
Featured Publication
Individuals with Down syndrome (DS) exhibit a cholinergic deficiency similar to that found in Alzheimer's disease. Cholinesterase inhibitors, used to treat Alzheimer's disease, may improve cognitive function in individuals with DS. This is the first invest ...
Full textLink to itemCite
Journal ArticleAm J Med Genet C Semin Med Genet · August 15, 2006
Featured Publication
Clinical and translational research play a key role in the transition of basic research discoveries to effective therapies. In Down syndrome (DS), these research approaches are not well utilized or developed to test new therapies to improve cognitive and/o ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · April 1, 2006
Featured Publication
Females with the fragile X full mutation have been reported to have difficulty learning mathematics. Women with the fragile X premutation often give a history of mathematics difficulties in themselves especially with higher level math. In order to evaluate ...
Full textLink to itemCite
Journal ArticleJ Genet Couns · February 2004
Genetic testing in minor children presents a complex ethical and social problem. Current guidelines state that genetic testing of children is recommended only under circumstances where a clear medical or psychosocial benefit to the child can be demonstrate ...
Full textLink to itemCite
Journal ArticleAm J Med Genet A · January 15, 2003
At present, there is no proven pharmacologic treatment for cognitive or language impairments in Down syndrome (DS). Cholinergic deficits have been documented in DS and linked to cognitive deficits. This study is a 24-week open-label clinical trial of donep ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · June 1, 2002
This study explored age preferences about when to learn at-risk status and have carrier testing in women who were undergoing testing for fragile X. Forty-two women (20 carriers and 22 noncarriers) completed a structured interview prior to carrier testing a ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · January 1, 2001
This paper reports the results of a longitudinal study of women at-risk to inherit the fragile X mutation. It addresses 1) how upsetting the women perceived their carrier information to be, 2) how serious a problem they perceive fragile X syndrome to be, a ...
Link to itemCite
Journal ArticleAm J Med Genet · June 19, 2000
The purpose of the study was to explore self-concept in women at risk for inheriting the fragile X mutation. Time 1 measures were obtained prior to carrier testing and Time 2 measures were collected approximately 5 months after learning carrier status. The ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · June 5, 2000
Fragile X syndrome is the leading form of hereditary mental retardation, but the condition is still underdiagnosed in young children. Because of concern that the fragile X phenotype is subtle in young boys and therefore contributes to underdiagnosis of the ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · January 29, 1999
Sixty-five parents of individuals affected by fragile X syndrome who attended the National Fragile X Conference in Portland, Oregon (1996), were asked to complete a survey assessing parental level of concern about carrier testing in children at risk for fr ...
Link to itemCite
Journal ArticleAm J Med Genet · January 10, 1997
This study surveyed obligate carriers of the fragile X syndrome fra(X) to ascertain opinions and attitudes regarding carrier testing. Female carriers of fra(X) syndrome were recruited during their visits to the Fragile X Clinic at Duke University Medical C ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · August 9, 1996
Fragile X DNA studies were carried out on all obligate carriers of a large fragile X family with 10 mentally retarded individuals. One 64-year-old carrier man with an altered FMR-1 allele was not described as being mentally retarded or as having any limita ...
Full textLink to itemCite
Journal ArticleJ Autism Dev Disord · June 1996
We conducted two multicenter studies on adaptive trajectories and profiles in males with fragile X syndrome. Study 1 longitudinally assessed 29 males ages 1-20 years using age-equivalent scores from the Vineland Adaptive Behavior Scales. Fragile X boys age ...
Full textLink to itemCite
Journal ArticleAm J Med Genet · November 20, 1995
Fryns syndrome is an autosomal recessive multiple congenital anomaly syndrome characterized by diaphragmatic hernia, unusual facies, and distal limb hypoplasia. It was first reported as a lethal condition. We report on a three-year-old survivor with Fryns ...
Full textLink to itemCite
Journal ArticleAm J Ment Retard · March 1994
To determine whether aberrant behaviors described in boys with fragile X syndrome distinguish them from other boys with developmental disabilities, we asked the primary caregivers of 55 boys with fragile X and 57 matched controls to complete five behaviora ...
Link to itemCite
Journal ArticleAm J Hum Genet · October 1993
DNA at the FMR-1 locus was analyzed by Southern blot using probe StB12.3 in an unusual fragile X family with six brothers, three of whom are affected with fragile X to varying degrees, two of whom are nonpenetrant carriers, and one of whom is unaffected. F ...
Link to itemCite
Journal ArticleAm J Ment Retard · November 1987
Retrospective, longitudinal data were obtained on 21 boys with the fragile X syndrome to assess whether their IQs declined during childhood. For the group as a whole, IQs dropped significantly; 13 boys showed a significant decline at retest. Our results ar ...
Link to itemCite
Journal ArticleJ Pers Soc Psychol · March 1983
This study was conducted to examine (a) differences in physiological response of Type A and Type B individuals to conditions that varied in both controllability and consistency of controllability over an aversive stimulus and (b) whether Type A relative to ...
Full textLink to itemCite
Journal ArticleJournal of Research in Personality · January 1, 1982
Previous research has investigated two diverse operational definitions of stress, experimentally induced, short-term stress and long-term, life stress. The purpose of this study was to intersect these two research methodologies and determine the effect of ...
Full textCite
Journal ArticleInternational Journal of Behavioral Development · January 1, 1980
Relationships between measures of visual habituation and performance on cognitive tasks at 51 months of age and between these and previous assessments (at 39, 27, 15 months and early infancy) were examined in 24 children. Results suggest that youngsters cu ...
Full textCite